Sign inThe healthcare investment firm's acquisition of the business closed November 3, 2026, with the unit now operating independently under the Biomark Scientific name.
SEC filing
PTC Therapeutics said on November 3, 2026, that its board cleared a program to repurchase up to $500 million in common stock as conditions allow.
SEC filing
Arvinas began dosing patients in a Phase 1/2 trial of its HPK1 degrader ARV-6723 and reaffirmed plans for data from three Phase 1 programs by 2027.
SEC filing (3)
Dr. Jiong Ma, Gautam Patel and Dr. Adrian Senderowicz stepped down from Anavex's board effective October 28, 2026, and the board reconstituted its committees days later.
SEC filing (2)
Pfizer lifted full-year revenue and EPS guidance on third-quarter results and detailed regulatory approvals for Talzenna, Tukysa and a positive Elrexfio Phase 3 readout.
SEC filing (9)
The transition reflects a company where IM8 now accounts for nearly all revenue, with finance leadership shifting to the United States.
SEC filing
Compass said its rolling NDA for COMP360 in treatment-resistant depression will be completed within two weeks, with launch still targeted for the first half of 2027.
SEC filing
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)
Beam says a BLA for risto-cel could come as early as year-end 2026, with pivotal dosing for BEAM-302 completing in the first half of 2027 and BEAM-304 dosing starting in early 2027.
SEC filing
Amneal reported third-quarter net revenue of $863 million and lifted its full-year 2026 outlook as new product launches and the Kashiv acquisition fed growth.
SEC filing (2)
Rhythm posted $92.1 million in quarterly IMCIVREE sales, amended its LG Chem licensing deal, secured a $750 million loan facility, and plans a bivamelagon Phase 3 trial in acquired HO by year-end.
SEC filing
Denali reported Q3 2026 results showing AVLAYAH's second full commercial quarter alongside progress on five TransportVehicle pipeline programs expected to yield data in 2027.
SEC filing
The company highlighted ADHD proof-of-concept data and a new phase 2 depression trial for its orexin 2 receptor agonists alongside quarterly earnings.
SEC filing
The company filed a prospectus supplement on November 2, 2026 to raise the amount it can sell under its existing at-the-market agreement with WallachBeth Capital.
SEC filing (2)
Madrigal also outlined a new Phase 3 trial in well-compensated MASH cirrhosis and reported cash of $961.8 million as of Sept. 30, 2026.
SEC filing
The company expects about $6.2 million in gross proceeds as holders agree to exercise repriced two-year warrants ahead of their November expiration.
SEC filing
Kairos amended its equity line of credit arrangement with Helena Global Investment Opportunities for a third time while its CSO presented interim trial data on carotuximab.
SEC filing
In patients 64 and older, 79.2% of Allocetra recipients showed a clinically meaningful response at 12 months versus 47.6% on placebo, Enlivex said.
SEC filing (2)
Karyopharm entered a restructuring support agreement with lenders and noteholders setting up a merger with Ayrmid, with the deal expected to close in Q1 2027.
SEC filing
Inovio said it expects to ship the RRP immunotherapy in about 60 days and must submit a confirmatory study protocol to the FDA by the end of 2026.
SEC filing, FDA press release (2)
Theriva gets a $350,000 upfront payment plus up to $91 million in milestones and a separately capped royalty stream as Biossil takes over development of the antibiotic-degrading enzyme programs.
SEC filing
The agreement, tied to Nuclea Canada's purchase of Moltex Energy's assets, is linked to a pending SPAC merger involving an affiliated sponsor entity.
SEC filing
The approval, announced October 30, 2026, arrived ahead of a November 10 FDA goal date and targets a drug formulation free of a controversial preservative.
SEC filing
The open-label extension trial, which had enrolled 42 participants, was stopped as of a business decision unrelated to safety or efficacy, according to the registry record updated November 2, 2026.
ClinicalTrials.gov
John Moorhead joins Femasys's board as a designee of Nantahala Capital Management, replacing Kenneth Eichenbaum, whose seat was tied to a since-terminated nomination right held by Pointillist Global Macro Series.
SEC filing
Tevogen Inc. amended its credit facility with The Patel Family, LLP, converted all outstanding debt into common stock, and awarded CEO Ryan Saadi a restricted stock grant tied to $1.0 billion in revenue by 2031.
SEC filing
Vertex lifted full-year revenue guidance to $13.15-$13.25 billion and said a decision on povetacicept in IgA nephropathy is due from the FDA on November 30, 2026.
SEC filing
Krystal posted $127.3 million in third-quarter VYJUVEK sales, reported early KB113 tumor regression data in Gorlin syndrome patients, and set a $400 million share repurchase program.
SEC filing
The Eurasian Patent Office notified readiness to grant claims covering OCRL-deficiency diseases, including Lowe syndrome and Dent disease 2, under Can-Fite's deal with Fondazione Telethon.
SEC filing
Davis is stepping down after being named CEO of Align Technology, with AbbVie stating the move is unrelated to any internal dispute.
SEC filing
The company posted positive driving-study data for GlyphAllo and dosed its first GAD patient with GlyphAgo, while reporting $403.8 million in cash as of September 30, 2026.
SEC filing
Total net product revenue reached $259.7 million as Axsome began a Phase 3 trial of AXS-05 for smoking cessation and reported progress across its CNS pipeline.
SEC filing
Chairman Charles Nuzum and two other directors resigned effective October 27, 2026, and CEO Christopher Miglino took over as board chair on November 1.
SEC filing
The neurostimulation device maker said it will work with the behavioral health provider to expand access to its Deep TMS therapies, as filed with the SEC on November 2, 2026.
SEC filing
CorMedix cited a new CMS final rule setting a $8.32 per-session Q1 2027 add-on for DefenCath, and said it expects the rate to dip in Q2 before rising later in the year.
SEC filing
The agency assigned a PDUFA date of May 1, 2027 for ifezuntirgene inilparvovec, which would be the first disease-modifying treatment for the disease if cleared.
SEC filing
Neurocrine reported 41% revenue growth for the third quarter of 2026 and lifted full-year INGREZZA guidance while advancing new obesity and Alzheimer's programs.
SEC filing
The two disclosures, filed together in an 8-K dated October 28, 2026, cover a reduced settlement payment to Novartis and Allarity's first commercial contract under its new laboratory services strategy.
SEC filing
Third-quarter revenue rose 32% to $1.025 billion as FDA set a May 30, 2027 action date for VOXZOGO in HCH and BioMarin added a new Fabry asset to its pipeline.
SEC filing (2)
Third-quarter 2026 update details REC-4881 polyp reductions in FAP, early REC-1245 responses, a Sanofi development-candidate option, and cash runway extended into 2029.
SEC filing
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
The Paris biotech detailed progress on a planned obesity trial and a Hong Kong joint venture for sarcopenia, while extending its projected cash runway into early 2028.
SEC filing
Supernus Pharmaceuticals said its common stock will be removed from Nasdaq following completion of a merger on November 2, 2026.
SEC filing
Syndax posted $83.3 million in total third-quarter revenue and outlined a slate of fourth-quarter revumenib data readouts as Keith Goldan prepares to hand the CFO role to Aaron Ondrey.
SEC filing
The Euronext- and Nasdaq-listed biotech appointed Shahidi as a non-executive independent director effective November 2, 2026, replacing Paulo Fontoura.
SEC filing
Travere posted $200.2 million in FILSPARI net product sales and said enrollment continues in its pivotal pegtibatinase trial, with a civorebrutinib IND planned by year-end.
SEC filing
The endocrine and rare disease drugmaker named the former Viatris and Pfizer executive to a newly created board seat and its audit committee, effective November 2, 2026.
SEC filing
The company will use proceeds for working capital, subsidiary funding, and a $625,000 settlement with Lind Global Fund II tied to prior litigation.
SEC filing